Videos

Sarah Murawski, MPAS, discusses how telemedicine can impact the use of chimeric antigen receptor T-cell therapy in patients with cancer at the Association of Community Cancer Centers National Oncology Conference.

Zofia Piotrowska, MD, MHS, a medical oncologist at Massachusetts General Hospital and an instructor at Harvard Medical School, discusses the results from the phase III RELAY trial that investigated first-generation EGFR inhibitor erlotinib plus the VGEF-directed antibody ramucirumab in patients with EGFR-mutant lung cancer.<br /> &nbsp;